Ignacio Melero

Presentation(s):

• SO-12: Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040

  Thursday, June 30, 2022
  15:42 – 15:50